|
JP5658230B2
(ja)
|
2009-04-13 |
2015-01-21 |
インサーム（インスティテュート ナショナル デ ラ セント エ ドゥ ラ ルシェルシュ メディカル） |
Ｈｐｖ粒子およびその使用
|
|
WO2014117121A1
(en)
|
2013-01-28 |
2014-07-31 |
St. Jude Children's Research Hospital, Inc. |
A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
|
|
EP4059521A1
(en)
|
2013-09-18 |
2022-09-21 |
Aura Biosciences, Inc. |
Virus-like particle conjugates for diagnosis and treatment of tumors
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
EP3071221A1
(en)
|
2013-11-21 |
2016-09-28 |
UCL Business Plc. |
Cell
|
|
RU2701346C1
(ru)
|
2013-12-06 |
2019-09-25 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
|
|
CA2933707A1
(en)
|
2013-12-20 |
2015-06-25 |
Fred Hutchinson Cancer Research Center |
Tagged chimeric effector molecules and receptors thereof
|
|
US11385233B2
(en)
|
2015-03-05 |
2022-07-12 |
Autolus Limited |
Methods of depleting malignant T-cells
|
|
US20230027993A1
(en)
|
2014-03-05 |
2023-01-26 |
Autolus Limited |
Methods
|
|
GB201403972D0
(en)
|
2014-03-06 |
2014-04-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
NZ739448A
(en)
|
2014-04-10 |
2019-10-25 |
Seattle Children’S Hospital Dba Seattle Children’S Res Institute |
Transgene genetic tags and methods of use
|
|
CA2948462A1
(en)
|
2014-05-15 |
2015-11-19 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
GB201506423D0
(en)
|
2015-04-15 |
2015-05-27 |
Tc Biopharm Ltd |
Gamma delta T cells and uses thereof
|
|
AU2015289644A1
(en)
|
2014-07-15 |
2017-02-02 |
Juno Therapeutics, Inc. |
Engineered cells for adoptive cell therapy
|
|
GB201415347D0
(en)
*
|
2014-08-29 |
2014-10-15 |
Ucl Business Plc |
Signalling system
|
|
WO2016097231A2
(en)
*
|
2014-12-17 |
2016-06-23 |
Cellectis |
INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
|
|
KR102376244B1
(ko)
*
|
2014-12-24 |
2022-03-21 |
오토러스 리미티드 |
세포
|
|
CA2973529A1
(en)
|
2015-01-26 |
2016-08-04 |
Cellectis |
Cll1-specific multi-chain chimeric antigen receptor
|
|
WO2016123143A1
(en)
*
|
2015-01-26 |
2016-08-04 |
The University Of Chicago |
CAR T-CELLS RECOGNIZING CANCER-SPECIFIC IL 13Rα2
|
|
JP6895380B2
(ja)
|
2015-02-06 |
2021-06-30 |
ナショナル ユニバーシティ オブ シンガポール |
治療免疫細胞の有効性を改良するための方法
|
|
IL254141B
(en)
*
|
2015-02-27 |
2022-07-01 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (cars) focusing on hematological malignancies, preparations and methods for their use
|
|
HUE059218T2
(hu)
*
|
2015-04-08 |
2022-11-28 |
Novartis Ag |
CD20-terápiák, CD22-terápiák és kombinációs terápiák CD19 kiméra antigénreceptort (CAR-t) expresszáló sejttel
|
|
MA41962A
(fr)
|
2015-04-23 |
2018-02-28 |
Baylor College Medicine |
Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t
|
|
GB201507119D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507115D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic Acid Construct
|
|
GB201507108D0
(en)
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
GB201507111D0
(en)
*
|
2015-04-27 |
2015-06-10 |
Ucl Business Plc |
Nucleic acid construct
|
|
EP3288570A4
(en)
*
|
2015-04-29 |
2018-11-21 |
Fred Hutchinson Cancer Research Center |
Modified stem cells and uses thereof
|
|
GB201507368D0
(en)
|
2015-04-30 |
2015-06-17 |
Ucl Business Plc |
Cell
|
|
WO2016187158A1
(en)
*
|
2015-05-15 |
2016-11-24 |
City Of Hope |
Chimeric antigen receptor compositions
|
|
CN108174607A
(zh)
*
|
2015-05-29 |
2018-06-15 |
朱诺治疗学股份有限公司 |
用于遗传工程改造的细胞中调节抑制性相互作用的组合物和方法
|
|
GB201509413D0
(en)
*
|
2015-06-01 |
2015-07-15 |
Ucl Business Plc |
Fusion protein
|
|
KR102526538B1
(ko)
*
|
2015-06-10 |
2023-04-28 |
이뮤너티바이오, 인크. |
암을 치료하기 위한 변형된 nk-92 세포
|
|
US11173179B2
(en)
|
2015-06-25 |
2021-11-16 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
|
|
TW202444897A
(zh)
*
|
2015-06-25 |
2024-11-16 |
美商生物細胞基因治療有限公司 |
嵌合抗原受體(car)、組合物及其使用方法
|
|
MA42895A
(fr)
*
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
GB201513540D0
(en)
|
2015-07-31 |
2015-09-16 |
King S College London |
Therapeutic agents
|
|
WO2017027291A1
(en)
*
|
2015-08-07 |
2017-02-16 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Bispecific car t-cells for solid tumor targeting
|
|
GB201514874D0
(en)
|
2015-08-20 |
2015-10-07 |
Autolus Ltd |
Cell
|
|
US20180264038A1
(en)
|
2015-09-28 |
2018-09-20 |
Regents Of The University Of Minnesota |
Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity
|
|
GB201518817D0
(en)
*
|
2015-10-23 |
2015-12-09 |
Autolus Ltd |
Cell
|
|
US11207339B2
(en)
|
2015-10-30 |
2021-12-28 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Targeted cancer therapy
|
|
GB201519900D0
(en)
*
|
2015-11-11 |
2015-12-23 |
Ucl Business Plc |
Chimeric antigen receptor
|
|
US20200281973A1
(en)
*
|
2016-03-04 |
2020-09-10 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
|
US11400116B2
(en)
|
2016-05-06 |
2022-08-02 |
The Regents Of The University Of California |
Systems and methods for targeting cancer cells
|
|
EP3458077A4
(en)
*
|
2016-05-17 |
2020-04-01 |
Chimera Bioengineering Inc. |
METHODS OF MANUFACTURING NEW AREAS OF ANTIGEN BINDING
|
|
US20200283534A1
(en)
|
2016-06-24 |
2020-09-10 |
iCell Gene Therapeuticics LLC |
CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS THEREOF
|
|
ES2981703T3
(es)
*
|
2016-09-02 |
2024-10-10 |
Lentigen Tech Inc |
Composiciones y métodos para tratar cáncer con DuoCars
|
|
US20190359989A1
(en)
*
|
2016-09-09 |
2019-11-28 |
Carsgen Therapeutics Co., Ltd. |
Fusion protein and applications thereof
|
|
EP3519443A4
(en)
*
|
2016-09-30 |
2020-06-10 |
Baylor College of Medicine |
CHIMERIC ANTIGEN RECEPTOR THERAPY WITH REDUCED CYTOTOXICITY FOR VIRAL DISEASE
|
|
CA3039646A1
(en)
|
2016-10-07 |
2018-04-12 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
|
JP2019535262A
(ja)
*
|
2016-11-11 |
2019-12-12 |
オートラス リミテッド |
キメラ抗原受容体
|
|
CN118562882B
(zh)
|
2016-11-22 |
2025-08-08 |
新加坡国立大学 |
用于t细胞恶性肿瘤免疫疗法的cd7表达阻滞剂和嵌合抗原受体
|
|
CN110291200B
(zh)
|
2016-12-12 |
2024-05-14 |
西雅图儿童医院（Dba西雅图儿童研究所） |
对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体
|
|
EP3568406A4
(en)
*
|
2017-01-10 |
2020-10-21 |
The General Hospital Corporation |
T LYMPHOCYTES EXPRESSING A CHEMERICAL ANTIGENIC RECEPTOR
|
|
CN110582509A
(zh)
*
|
2017-01-31 |
2019-12-17 |
诺华股份有限公司 |
使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
|
|
EP3600356A4
(en)
|
2017-03-27 |
2020-12-23 |
National University of Singapore |
TRUNCATED NKG2D CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLER CELL IMMUNOTHERAPY
|
|
KR102624509B1
(ko)
|
2017-03-27 |
2024-01-12 |
싱가포르국립대학교 |
자연 살해 세포의 ex vivo 확장 및 활성화를 위한 자극성 세포주
|
|
CN110914289B
(zh)
*
|
2017-05-12 |
2024-05-14 |
克里斯珀医疗股份公司 |
用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途
|
|
GB201707783D0
(en)
*
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
CN110621694A
(zh)
*
|
2017-05-15 |
2019-12-27 |
奥托路斯有限公司 |
包含嵌合抗原受体(car)的细胞
|
|
GB201707779D0
(en)
|
2017-05-15 |
2017-06-28 |
Autolus Ltd |
Cell
|
|
US12275787B2
(en)
|
2017-06-21 |
2025-04-15 |
Icell Gene Therapeutics Llc |
Chimeric antigen receptors (CARs), compositions and methods thereof
|
|
AU2018311345A1
(en)
*
|
2017-08-02 |
2020-02-27 |
Autolus Limited |
Cells expressing a chimeric antigen receptor or engineered TCR and comprising a nucleotide sequence which is selectively expressed
|
|
US20190038733A1
(en)
|
2017-08-10 |
2019-02-07 |
National University Of Singapore |
T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
|
|
JP2020535814A
(ja)
|
2017-09-28 |
2020-12-10 |
インパクト−バイオ リミテッド |
阻害性キメラ抗原受容体（ｉＣＡＲ）を調製するための普遍的プラットフォーム
|
|
EP3694886A4
(en)
*
|
2017-10-12 |
2021-09-22 |
iCell Gene Therapeutics, LLC |
COMPOSITE CHIMERIC ANTIGEN RECEPTOR (CCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USING THEREOF
|
|
WO2019084248A1
(en)
|
2017-10-25 |
2019-05-02 |
Actinium Pharmaceuticals, Inc. |
METHODS OF ANTI-CD45-BASED LYMPHODEPPLICATION AND USES THEREOF IN COMBINATION WITH ACT-BASED ANTICANCER THERAPIES
|
|
GB201717524D0
(en)
|
2017-10-25 |
2017-12-06 |
Autolus Ltd |
Vectors
|
|
BR112020008638A2
(pt)
|
2017-11-01 |
2020-10-20 |
Juno Therapeutics Inc |
receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
|
|
JP7360174B2
(ja)
|
2018-02-09 |
2023-10-12 |
ナショナル ユニヴァーシティー オブ シンガポール |
ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
|
|
GB201803079D0
(en)
*
|
2018-02-26 |
2018-04-11 |
Autolus Ltd |
Cell
|
|
WO2019177986A1
(en)
*
|
2018-03-12 |
2019-09-19 |
Nantkwest, Inc. |
Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
PE20210666A1
(es)
|
2018-05-11 |
2021-03-31 |
Crispr Therapeutics Ag |
Metodos y composiciones para tratar el cancer
|
|
EP3794034A1
(en)
|
2018-05-15 |
2021-03-24 |
Autolus Limited |
Chimeric antigen receptor
|
|
GB201807870D0
(en)
|
2018-05-15 |
2018-06-27 |
Autolus Ltd |
A CD79-specific chimeric antigen receptor
|
|
AU2019275076B2
(en)
|
2018-05-23 |
2024-12-19 |
National University Of Singapore |
Blockade of CD2 surface expression and expression of chimeric antigen receptors for immunotherapy of T-cell malignancies
|
|
CN110615842B
(zh)
*
|
2018-06-20 |
2023-05-09 |
上海隆耀生物科技有限公司 |
一种包含共刺激受体的嵌合抗原受体及应用
|
|
GB201813178D0
(en)
|
2018-08-13 |
2018-09-26 |
Autolus Ltd |
Cell
|
|
CN112601758A
(zh)
|
2018-08-29 |
2021-04-02 |
新加坡国立大学 |
特异性刺激经基因修饰免疫细胞的存活和扩增的方法
|
|
CA3113896A1
(en)
|
2018-09-27 |
2020-04-02 |
Autolus Limited |
Chimeric antigen receptor
|
|
EP3632461A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
CA3112310C
(en)
*
|
2018-10-05 |
2025-05-06 |
Universitat Fur Bodenkultur Wien |
CHIMERIC ANTIGEN RECEPTOR GROUP (CAR)
|
|
EP3860643A1
(en)
*
|
2018-10-05 |
2021-08-11 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
EP3632460A1
(en)
*
|
2018-10-05 |
2020-04-08 |
St. Anna Kinderkrebsforschung |
A group of chimeric antigen receptors (cars)
|
|
GB201816522D0
(en)
|
2018-10-10 |
2018-11-28 |
Autolus Ltd |
Methods and reagents for analysing nucleic acids from single cells
|
|
SG11202104188VA
(en)
|
2018-11-01 |
2021-05-28 |
Juno Therapeutics Inc |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
|
JP7386382B2
(ja)
|
2018-12-12 |
2023-11-27 |
カイト ファーマ インコーポレイテッド |
キメラ抗原受容体及びｔ細胞受容体並びに使用方法
|
|
CN113347991B
(zh)
|
2019-01-23 |
2024-07-30 |
美天施生物科技有限两合公司 |
用于消除和增强受试者骨髓中造血干细胞植入的组合物的组合
|
|
CN118546959A
(zh)
|
2019-03-05 |
2024-08-27 |
恩卡尔塔公司 |
Cd19定向性嵌合抗原受体及其在免疫疗法中的用途
|
|
US20220145325A1
(en)
|
2019-03-08 |
2022-05-12 |
Autolus Limited |
Compositions and methods comprising engineered chimeric antigen receptor and modulator of car
|
|
GB201903237D0
(en)
|
2019-03-08 |
2019-04-24 |
Autolus Ltd |
Method
|
|
SG11202111130SA
(en)
|
2019-04-30 |
2021-11-29 |
Senti Biosciences Inc |
Chimeric receptors and methods of use thereof
|
|
JP7717619B2
(ja)
*
|
2019-05-01 |
2025-08-04 |
パクト ファーマ インコーポレイテッド |
Ｃｄ８改変ｔ細胞療法を使用するがんの治療のための組成物及び方法
|
|
CA3140064A1
(en)
*
|
2019-05-16 |
2020-11-19 |
University Of Washington |
Lockr-mediated recruitment of car t cells
|
|
GB201909144D0
(en)
|
2019-06-25 |
2019-08-07 |
Autolus Ltd |
Culture medium
|
|
GB201910185D0
(en)
|
2019-07-16 |
2019-08-28 |
Autolus Ltd |
Method
|
|
US20220257757A1
(en)
|
2019-07-16 |
2022-08-18 |
Autolus Limited |
Method for preconditioning a subject who is about to receive a t-cell therapy
|
|
US20220289842A1
(en)
*
|
2019-08-20 |
2022-09-15 |
Senti Biosciences, Inc. |
Chimeric inhibitory receptor
|
|
WO2021044213A2
(en)
*
|
2019-09-05 |
2021-03-11 |
Migal-galilee Research Institute Ltd. |
Blocking chimeric antigen receptors for prevention of undesired activation of effector and regulatory immune cells
|
|
EP4031583A4
(en)
*
|
2019-09-16 |
2023-11-15 |
Fred Hutchinson Cancer Center |
CHIMERIC RECEPTOR PROTEINS AND THEIR USES
|
|
US20240122979A1
(en)
*
|
2019-10-08 |
2024-04-18 |
Provincial Health Services Authority |
Chimeric Cytokine Receptors
|
|
US20220411535A1
(en)
*
|
2019-11-26 |
2022-12-29 |
University Of Utah Research Foundation |
Compositions and methods for upregulating hla class i on tumor cells
|
|
IL292924A
(en)
|
2019-11-26 |
2022-07-01 |
Novartis Ag |
Cd19 and cd22 chimeric antigen receptors and uses thereof
|
|
IL293716A
(en)
|
2019-12-11 |
2022-08-01 |
A2 Biotherapeutics Inc |
Lilrb1-based chimeric antigen receptor
|
|
CN115066249A
(zh)
|
2020-02-04 |
2022-09-16 |
美天施生物科技有限两合公司 |
表达用于感测可溶性抗原的适体嵌合抗原受体的免疫细胞
|
|
EP4107175A4
(en)
*
|
2020-02-20 |
2024-03-20 |
Senti Biosciences, Inc. |
ARCHITECTURES OF INHIBITORY CHIMERIC RECEPTORS
|
|
WO2021168298A1
(en)
*
|
2020-02-20 |
2021-08-26 |
Senti Biosciences, Inc. |
Inhibitory chimeric receptor architectures
|
|
GB202007044D0
(en)
|
2020-05-13 |
2020-06-24 |
Autolus Ltd |
Method
|
|
US12286465B2
(en)
|
2020-05-28 |
2025-04-29 |
Miltenyi Biotec B.V. & Co. KG |
Chimeric antigen receptor with a spacer comprising C2-set Ig-like domains
|
|
GB202008957D0
(en)
|
2020-06-12 |
2020-07-29 |
Autolus Ltd |
Culture medium
|
|
WO2022016119A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
|
AU2021329371A1
(en)
*
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating mesothelin positive cancers
|
|
IL300629A
(en)
|
2020-08-20 |
2023-04-01 |
A2 Biotherapeutics Inc |
Preparations and methods for the treatment of EGFR positive cancer
|
|
AU2021329375A1
(en)
|
2020-08-20 |
2023-04-20 |
A2 Biotherapeutics, Inc. |
Compositions and methods for treating ceacam positive cancers
|
|
US11976297B2
(en)
*
|
2020-09-21 |
2024-05-07 |
A2 Biotherapeutics, Inc. |
Engineered immune cells with receptor cross-talk
|
|
WO2022081975A1
(en)
*
|
2020-10-15 |
2022-04-21 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for inhibition of natural killer cell receptors
|
|
WO2022096664A1
(en)
|
2020-11-09 |
2022-05-12 |
Miltenyi Biotec B.V. & Co. KG |
Methods and compositions for eliminating engineered immune cells
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
JP2024500847A
(ja)
|
2020-12-18 |
2024-01-10 |
センチュリー セラピューティクス，インコーポレイテッド |
適合可能な受容体特異性を有するキメラ抗原受容体システム
|
|
WO2022144632A1
(en)
|
2020-12-30 |
2022-07-07 |
Crispr Therapeutics Ag |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN117597358A
(zh)
|
2021-02-16 |
2024-02-23 |
A2生物治疗股份有限公司 |
用于治疗her2阳性癌症的组合物和方法
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
JP2024520430A
(ja)
*
|
2021-05-26 |
2024-05-24 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
阻害性キメラ抗原受容体は養子細胞治療のオンターゲット・オフ腫瘍効果を防止する
|
|
US20240336903A1
(en)
*
|
2021-08-19 |
2024-10-10 |
Shandong Boan Biotechnology Co., Ltd. |
Fusion Proteins for Dephosphorylating Proteins that Regulate T Cell Activation through the TCR Signaling Pathway
|
|
GB202112923D0
(en)
|
2021-09-10 |
2021-10-27 |
Ucl Business Ltd |
Binding domain
|
|
US20250235477A1
(en)
|
2021-10-06 |
2025-07-24 |
Miltenyi Biotec B.V. & Co. KG |
Method for targeted gene insertion into immune cells
|
|
WO2023218381A1
(en)
|
2022-05-11 |
2023-11-16 |
Autolus Limited |
Cd19/22 car t-cell treatment of high risk or relapsed pediatric acute lymphoblastic leukemia
|
|
GB202209920D0
(en)
|
2022-07-06 |
2022-08-17 |
Autolus Ltd |
Cell
|
|
WO2024078995A1
(en)
|
2022-10-15 |
2024-04-18 |
Miltenyi Biotec B.V. & Co. KG |
Transduction of gammadelta t cells with pseudotyped retroviral vectors
|
|
EP4520346A1
(en)
|
2023-09-06 |
2025-03-12 |
Gyncentrum Sp. z o.o. |
Cells, methods and systems for use in the treatment of a cancer with dual-car-t
|
|
GB202403564D0
(en)
|
2024-03-12 |
2024-04-24 |
Autolus Ltd |
Method
|
|
NL2037811B1
(en)
|
2024-05-29 |
2025-12-12 |
Univ Oslo |
Treatment for Cancer
|
|
WO2025259108A1
(en)
|
2024-06-11 |
2025-12-18 |
Prinses Máxima Centrum Voor Kinderoncologie B.V. |
Brain organoid
|